ELI LILLY AND COMPANY Deferred Income Tax Liabilities, Net
ELI LILLY AND COMPANY (LLY) had Deferred Income Tax Liabilities, Net of $87.30 million as of 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2023-02-22
- 2022-12-31: Deferred Income Tax Liabilities, Net $87.30M.
- 2022-09-30: Deferred Income Tax Liabilities, Net $171.90M.
- 2022-06-30: Deferred Income Tax Liabilities, Net $862.50M.
- 2022-03-31: Deferred Income Tax Liabilities, Net $1.29B.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2022-12-31 | $87.30M 10-K · filed 2023-02-22 |
| 2022-09-30 | $171.90M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $862.50M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.29B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $1.73B 10-K · filed 2023-02-22 |
| 2021-09-30 | $1.63B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $1.86B 10-Q · filed 2021-08-03 |
| 2021-03-31 | $2.20B 10-Q · filed 2021-04-30 |
| 2020-12-31 | $2.10B 10-K · filed 2022-02-23 |
| 2020-09-30 | $2.11B 10-Q · filed 2020-10-28 |
| 2020-06-30 | $2.04B 10-Q · filed 2020-07-31 |
| 2020-03-31 | $2.19B 10-Q · filed 2020-05-01 |
| 2019-12-31 | $2.19B 10-K · filed 2021-02-17 |
| 2019-09-30 | $2.41B 10-Q · filed 2019-10-25 |
| 2019-06-30 | $2.38B 10-Q · filed 2019-08-02 |
| 2019-03-31 | $2.40B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.31B 10-K · filed 2020-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |